BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Florence, Italy – March 9, 2026 Menarini Group, one of Europe’s leading pharmaceutical companies, has reported strong financial growth...
